Figure 5.

MYXV prolongs survival of mice engrafted with intraperitoneal tumors. (a) NOD/SCID mice engrafted with intraperitoneal Hs766T-FFluc tumors were divided into four treatment groups: MYXV-treated (virus) cohort received 5–6 doses of 10⁸ ffu; gemcitabine-treated mice (G) received four doses of 50 mg/kg of gemcitabine; the combination treatment cohort received gemcitabine followed by virus (G+V); mock treated mice received PBS. (b) C57Bl6 mice engrafted with intraperitoneal Pan02-FFluc tumors were treated with PBS (mock), MYXV only (virus), gemcitabine only (G) or with combination treatments involving gemcitabine followed by virus (G+V) or virus followed by gemcitabine (V+G). All treatments were administered IP and started after confirmation of tumor burden by bioluminescence imagining with D-luciferin 5–6 days after injection of cells into the IP cavity. *P < 0.05 between mock and MYXV treated groups; **P < 0.05 between MYXV and gemcitabine-treated groups; ***P < 0.05 between MYXV and V+G treated groups. ffu, foci forming units; MYXV, Myxoma virus; PBS, phosphate-buffered saline.